Popular Articles

Nile Therapeutics, Inc. Announces Dosing Of First Patient In Phase 2 Study Of CD-NP For The Treatment Of Acute Heart Failure
Nile Therapeutics, Inc. (Nasdaq: NLTX), a company focused on the development of novel therapeutics for heart failure patients, today announced dosing of its first patient in a Phase 2 clinical study of its lead product, CD-NP, for the treatment of acute heart failure.
diet pills
Deadly Leukemia Stem Cells Found And Eliminated By New Targeted Therapy
New research describes a molecular tool that shows great promise as a therapeutic for human acute myeloid leukemia (AML), a notoriously treatment-resistant blood cancer. The study, published by Cell Press in the July 2nd issue of the journal Cell Stem Cell, describes exciting preclinical studies in which a new therapeutic approach selectively attacks human cancer cells grown in the lab and in animal models of leukemia.
News of the day
Health Bills Create Tension Over Abortion Coverage
The Associated Press reports: "Health care legislation before Congress would allow a new government-sponsored insurance plan to cover abortions, a decision that would affect millions of women and recast federal policy on the divisive issue. Federal funds for abortions are now restricted to cases involving rape, incest or danger to the health of the mother. Abortion opponents say those restrictions should carry over to any health insurance sold through a new marketplace envisioned under the legislation, an exchange where people would choose private coverage or the public plan. Abortion rights supporters say that would have the effect of denying coverage for abortion to millions of women who now have it through workplace insurance and are expected to join the exchange. Advocates on both sides are preparing for a renewed battle over abortion, which could jeopardize political support for President Barack Obama"s health care initiative aimed at covering nearly 50 million uninsured and restraining medical costs" (Alonso-Zaldivar, 8/5).

New Plans To Improve Eating Disorder Services In Wales.

Two new specialist teams will be set up to improve diagnosis, care and support for people with eating disorders in Wales, Health Minister Edwina Hart officially announced. The new teams - for North Wales and South Wales - will comprise of specialist clinicians and work closely with existing services such as GPs surgeries, social services, child and adolescent mental health services and community mental health teams. Additional funding has been allocated to deliver this plan. ÷£0.5 million will be available this year for the recruitment of additional staff and extra training. After that, ÷£1 million will be available every year to sustain and develop services.

Swine Flu Daily Update Issued At: 11am Friday 10 July 2009, Wales.

The NPHS influenza surveillance scheme, which records reports of diagnoses of flu from more than 300 GP practices across Wales, shows low levels of influenza activity in all parts of Wales. Further detail can be found on the NPHS website: http://www.wales.nhs.uk/sites3/page.cfm?orgid=457&pid=38241 -- The report from 8 July estimates there were 12.2 cases of a flu-like illness diagnosed by GPs out of every 100,000 people in Wales - this is the equivalent of 366 people in Wales contacting their GPs in the last seven days with flu like symptoms. Not all of these people will have swine flu and not everyone with flu like symptoms will contact their GP. It is expected that the proportion of influenza cases diagnosed that are due to swine flu will increase as the virus spreads in Wales.

Bayer Unveils DIDGET(TM), The First And Only Blood Glucose Meter That Connects With The Nintendo DS(TM) Or DS(TM) Lite.

Bayer Diabetes Care in the UK and Ireland today unveils "DIDGET(TM), the first and only blood glucose meter for kids with diabetes that connects directly to Nintendo DS(TM) and Nintendo DS(TM) Lite gaming systems. The DIDGET meter is designed to help kids manage this lifelong condition by rewarding them for building consistent blood glucose testing habits and meeting personalised glucose target ranges. "One of the biggest challenges facing parents of children with diabetes is the constant struggle to instil the habit of regular blood glucose testing that is critical for consistent diabetes management," says John Gregory, Professor in Paediatric Endocrinology, Wales School of Medicine, Cardiff University. "Bayer"s DIDGET meter can help ease the parent/child tension that testing often creates by adding an element of fun and rewards to the routine. Because it is designed with children in mind, Bayer"s DIDGET meter can transform a child"s blood glucose testing experience from something they have to do into something they want to do.

NovImmune Successfully Completes NI-0801 Phase I Clinical Study.

NovImmune, an immunology-focused biotech company dedicated to the development of therapeutic monoclonal antibodies, announced the successful completion of the first phase I clinical study with its fully human monoclonal antibody NI-0801 targeting the chemokine IP-10 (CXCL10) in healthy volunteers. The randomized, doubleblinded, placebo controlled, single centre, phase I study of escalating single intravenous doses of NI-0801 in healthy volunteers (study NI-0801-01) demonstrated that NI-0801 is well tolerated at doses up to and including 20mg/kg. Chemokines are a group of low molecular weight proteins that induce the chemotaxis of different leukocytes to sites of injury or infection.